Learn more about our positive long-term MARINA-OLE™ del-desiran (AOC 1001) data including vHOT video and patient testimonials

Click here
Poster

2024 MDA Clinical and Scientific Conference

Initial results of the Phase 2 Open-Label Extension Study of AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA-OLE™

AOC 1001-mediated Reduction of DMPK Leads to Increase in Functional MBNL Levels, Improving Muscle Function in Patients with DM1

AOC 1044 as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 Skipping: EXPLORE44 Phase 1/2 Healthy Volunteer Data

Targeting DUX4 for Silencing with AOC for the Treatment of FSHD

Increasing Diversity in Clinical Trial Participation: An Exploration of Clinical Trial Site Engagement

Poster

2023 World Muscle Society Congress

Topline Safety and Efficacy Data Analysis of Phase 1/2 Clinical Trial Evaluating AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA™

AOC 1001 Demonstrates DMPK Reduction and Spliceopathy Improvement in a Phase 1/2 study in Myotonic Dystrophy Type 1 (DM1) (MARINA™️️️)

Topline Data Analysis of the Phase 1/2 Clinical Trial Evaluating AOC 1001 in Adult Patients with Myotonic Dystrophy Type 1: MARINA™️️️

Phase 1/2 Trial Evaluating AOC 1044 in Healthy Volunteers and Participants with DMD Mutations Amenable to Exon 44 Skipping: EXPLORE44™️️️ Trial Design

Phase 1/2 Study to Evaluate AOC 1020 for Adult Patients with Facioscapulohumeral Muscular Dystrophy: FORTITUDE™️️️ Trial Design

Sex-related Utilization Differences in the 12-months After a Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD)

More Prevalent Comorbidities, Healthcare Costs, and Service Utilization in Male Myotonic Dystrophy (DM) Patients and Female Patients

Poster

2023 FSHD Society International Research Congress

Facioscapulohumeral Muscular Dystrophy (FSHD) Surgeries, Cardiovascular Testing, Mobility Aids and Healthcare Utilization After Diagnosis from a Real-World Data Analysis

Phase 1/2 Trial Evaluating AOC 1020 in Adults with FSHD: FORTITUDE Trial Design

AOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in Development for the Treatment of FSHD

Facioscapulohumeral Muscular Dystrophy (FSHD) Age-related Differences in Symptoms Among Patients Over and Under 40-Years

Poster

2023 MDA Clinical and Scientific Conference

Phase 1/2 Clinical Trial Evaluating the Safety and Pharmacokinetics of AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA Trial in Progress

AOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in Development for the Treatment of FSHD

Myotonic Dystrophy, Comorbid Conditions and Healthcare Utilization Based on a 5-Year Comparative Real-World Data Analysis

AOC 1044: An Antibody Oligonucleotide Conjugate as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 Skipping

Burden of Duchenne Muscular Dystrophy in Patients with Mutations Amenable to Exon 44 Skipping (DMD44)

Phase 1/2 Trial Evaluating AOC 1020 Safety and Pharmacokinetics in Adults with Facioscapulohumeral Muscular Dystrophy (FSHD): FORTITUDE Trial Design